BioSpace News Archive

Enanta Pharmaceuticals, Inc . today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for EDP-235, its coronavirus 3CL protease inhibitor (also known as the main coronavirus protease.

Ribon Therapeutics today announced the first patient has been dosed in the Phase 1b/2 study of RBN-2397 in combination with the anti-PD-1 checkpoint inhibitor therapy, pembrolizumab, in patients with squamous cell carcinoma of the lung (SCCL).

Taysha Gene Therapies, Inc. today announced the initiation of clinical development of TSHA-102 for the treatment of Rett syndrome under a recently approved Clinical Trial Application (CTA) by Health Canada.

Orphazyme A/S announces an update to the Company’s Financial Calendar for 2022, following that the Danish Business Authority upon request from the Company has approved to extend the deadline for the Company’s filing of its annual report for the financial year ended December 31, 2021, following the in-court restructuring proceedings of the Company (please see company announcements no. 10/2022 and 11/2022).

Artizan Biosciences, Inc. today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 11,299,790 that broadens the use of the company’s proprietary IgA-SEQ™ discovery platform.

Monte Rosa Therapeutics, Inc. today reported business highlights and financial results for the fourth quarter and full year, ended December 31, 2021.

Gain Therapeutics, Inc., a biotechnology company transforming the drug discovery paradigm with structurally targeted allosteric regulators identified with its proprietary computational discovery platform, presented new pre-clinical data from its Gaucher Disease program.

Laekna Therapeutics, a clinical-stage global biotechnology company，announced the appointment of Jeff Porter, Ph.D. as the Chairman of its Scientific Advisory Board.

ShouTi Inc., a clinical-stage global biopharmaceutical company developing novel oral therapeutics to treat a wide range of chronic diseases, announced the appointment of Sharon Tetlow to the company’s board of directors.

Australian biotech company Noxopharm (ASX:NOX) has announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to Veyonda ® , its lead oncology drug candidate , for use in the treatment of soft tissue sarcoma.